KLK3 and prostate cancer: Annual prostate cancer mortality was 1.3–2.1 times higher in black than white Americans in all four regions before mass utilization of PSA, with at least double the prostate cancer death rate in black versus white Americans in Atlanta, Detroit, and San Francisco.